as part of Integrated Supervised Injection Services Evaluation in Toronto, Ontario

Those requiring help injecting are at an elevated risk of injection-related injury and blood-borne infections and are thus a priority group for harm reduction programs. As supervised consumption services (SCS) are scaled-up across Canada, information on those who require help injecting is necessary to inform equitable service uptake. We characterised the sociodemographic, structural and drug use correlates of needing help injecting among a cohort of people who inject drugs in Toronto, Canada.

as part of Integrated Supervised Injection Services Evaluation in Toronto, Ontario

Studies of people who inject drugs (PWID) commonly use questionnaires to determine whether participants are currently, or have recently been, on opioid agonist treatment for opioid use disorder. However, these previously unvalidated self-reported treatment measures may be susceptible to inaccurate reporting.

as part of Toronto’s Drug Checking Service

Drug checking services (DCS) provide information on drug composition to inform consumption practices and monitor unregulated drug markets. We sought to identify correlates of recent informal DCS use (e.g., fentanyl test strips) and willingness to use a formal DCS (co-located within a supervised consumption site and employing laboratory-based analyses) in Toronto, Canada prior to its implementation.

as part of Preventing Injecting by Modifying Existing Responses (PRIMER)

As supervised consumption services (SCS) are scaled-up across Canada, information on those who require help injecting is necessary to inform equitable service uptake. We characterised the sociodemographic, structural and drug use correlates of needing help injecting among a cohort of people who inject drugs in Toronto, Canada.

as part of Toronto’s Drug Checking Service

This article reports on new synthetic cannabinoids (SCs) detected in drug samples submitted to Toronto’s Drug Checking Service (DCS) in Toronto, Canada, in the period following restrictions related to the COVID-19 pandemic in Ontario, during which global drug trafficking patterns are believed to have been affected.

as part of Integrated Supervised Injection Services Evaluation in Toronto, Ontario

In March 2020, following a provincial COVID-19 emergency declaration, modifications to opioid agonist treatment (OAT) were introduced in Ontario, Canada to promote treatment access amid the pandemic and ongoing opioid overdose crisis. Our objectives were to evaluate the effects of these modifications on OAT enrollment and on receipt of take-home doses and the frequency of urine drug screening among OAT-enrolled participants, as well as to investigate concurrent pre- and post-implementation trends in opioid-related overdoses and all-cause mortality.

as part of Toronto’s Drug Checking Service

This report presents early trends of samples analyzed within the first six months of drug checking service implementation in Toronto, Ontario. We sought to identify the prevalence of high-potency opioids in the unregulated drug supply and to identify noteworthy combinations thereof with stimulants, benzodiazepine-type drugs, and synthetic cannabinoids. We also present data on reported negative effects of samples (e.g., overdose).

as part of Systematic Reviews on Drug Policy

Given the growing availability of drug checking services and interest in their impacts, we conducted a systematic review to investigate the (a) influence of drug checking services on behaviour of people who use drugs, (b) monitoring of drug markets by drug checking services, and (c) outcomes related to models of drug checking services.

as part of Integrated Supervised Injection Services Evaluation in Toronto, Ontario

The Ontario Integrated Supervised Injection Services cohort in Toronto, Canada (OiSIS-Toronto) is an open prospective cohort of people who inject drugs established to evaluate the impacts of supervised consumption services integrated within three community health agencies on health status and service use.

as part of Toronto’s Drug Checking Service

We report the first detection of the psychoactive veterinary compound xylazine in Toronto, the largest urban center in Canada, by the city’s drug checking service.